Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.

Ocular Drug Delivery: Advancements and Innovations

Open access

Abstract

Ocular drug delivery has been significantly advanced for not only pharmaceutical compounds, such as steroids, nonsteroidal anti-inflammatory drugs, immune modulators, antibiotics, and so forth, but also for the rapidly progressed gene therapy products. For conventional non-gene therapy drugs, appropriate surgical approaches and releasing systems are the main deliberation to achieve adequate treatment outcomes, whereas the scope of “drug delivery” for gene therapy drugs further expands to transgene construct optimization, vector selection, and vector engineering. The eye is the particularly well-suited organ as the gene therapy target, owing to multiple advantages. In this review, we will delve into three main aspects of ocular drug delivery for both conventional drugs and adeno-associated virus (AAV)-based gene therapy products: (1) the development of AAV vector systems for ocular gene therapy, (2) the innovative carriers of medication, and (3) administration routes progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14091931

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Anatomical barriers of the eye. (A) In the anterior of the eye, the blood–aqueous barrier, consisting of the iris/ciliary blood vessels and nonpigmented ciliary epithelium, limits access to the anterior of the eye and prevents therapeutic entry to the intraocular environment. (B) In the posterior of the eye, the blood-retinal barrier, comprised of the retinal capillary endothelial cells and retinal pigment epithelium cells, prevents therapeutics from entering the posterior segment from the bloodstream.
Figure 1 Anatomical barriers of the eye. (A) In the anterior of the eye, the blood–aqueous barrier, consisting of the iris/ciliary blood vessels and nonpigmented ciliary epithelium, limits access to the anterior of the eye and prevents therapeutic entry to the intraocular environment. (B) In the posterior of the eye, the blood-retinal barrier, comprised of the retinal capillary endothelial cells and retinal pigment epithelium cells, prevents therapeutics from entering the posterior segment from the bloodstream.CC BY · PubMed Central
Figure 2 Schematic of the wild type and recombinant AAV genome. The wild type AAV genome comprised four known open reading frames, rep (blue), cap (green), MAAP (burgundy), and AAP (purple), flanked by inverted terminal repeats (ITRs, grey color). The rep gene encodes four regulatory proteins: Rep78, Rep68, Rep52, and Rep40. Cap gene encodes viral proteins, VP1, VP2, and VP3. Rep and cap genes are removed from the genome of recombinant AAV, instead the transgene expression cassette was inserted, flanked by ITRs. Created with BioRender.com.
Figure 2 Schematic of the wild type and recombinant AAV genome. The wild type AAV genome comprised four known open reading frames, rep (blue), cap (green), MAAP (burgundy), and AAP (purple), flanked by inverted terminal repeats (ITRs, grey color). The rep gene encodes four regulatory proteins: Rep78, Rep68, Rep52, and Rep40. Cap gene encodes viral proteins, VP1, VP2, and VP3. Rep and cap genes are removed from the genome of recombinant AAV, instead the transgene expression cassette was inserted, flanked by ITRs. Created with BioRender.com.CC BY · PubMed Central
Figure 3 The structure of organic nanoparticles (NPs). (A) Solid lipid nanoparticles (SLNs) range from 50 to 1000 nm and consist of a solid crystal lipid core that is stabilized by surfactant, which acts as an emulsifier. Rather than a simple phospholipid bilayer, the exterior of an SLN feature a bilayer of physiologic lipids, such as triglycerides and cholesterol. (B) Nanostructured lipid carriers (NLCs) range from 30 to 100 nm in size and have a similar outer layer to SLNs and contain a surfactant that acts as an emulsifier, but they utilize an irregular solid lipid crystal matrix and a liquid lipid (oil) core. (C) Polymeric nanoparticles range from 1 to 1000 nm. They utilize a polymetric core that can be loaded with active compounds to produce countless variations of the nanoparticle. (D) Dendrimers are organic polymers, which consist of a central core from which ‘branches’ extend outwards to form a spherical shape. They range from 1 to 10 nm in size.
Figure 3 The structure of organic nanoparticles (NPs). (A) Solid lipid nanoparticles (SLNs) range from 50 to 1000 nm and consist of a solid crystal lipid core that is stabilized by surfactant, which acts as an emulsifier. Rather than a simple phospholipid bilayer, the exterior of an SLN feature a bilayer of physiologic lipids, such as triglycerides and cholesterol. (B) Nanostructured lipid carriers (NLCs) range from 30 to 100 nm in size and have a similar outer layer to SLNs and contain a surfactant that acts as an emulsifier, but they utilize an irregular solid lipid crystal matrix and a liquid lipid (oil) core. (C) Polymeric nanoparticles range from 1 to 1000 nm. They utilize a polymetric core that can be loaded with active compounds to produce countless variations of the nanoparticle. (D) Dendrimers are organic polymers, which consist of a central core from which ‘branches’ extend outwards to form a spherical shape. They range from 1 to 10 nm in size.CC BY · PubMed Central
Figure 4 The structures of nanomicelles., liposomes, and niosomes (A) Surfactant micelles are grouped molecules of amphipathic lipids that create a hydrophobic core. Their sizes can vary but generally range from 10–100 nm. (B) Polymeric micelles contained amphiphilic copolymer that, when exposed to water, automatically forms a core/shell structure that can be loaded with insoluble drugs. They are typically between 10–100 nm in size. (C) Liposomes consist of an amphiphilic phospholipid bilayer that encloses hydrophilic substances and are typically between 25 and 2500 nm in size. (D) Niosomes are composed of non-ionic surfactant that form a vesicle to transport aqueous material. They are typically between 25 and 100 nm in size.
Figure 4 The structures of nanomicelles., liposomes, and niosomes (A) Surfactant micelles are grouped molecules of amphipathic lipids that create a hydrophobic core. Their sizes can vary but generally range from 10–100 nm. (B) Polymeric micelles contained amphiphilic copolymer that, when exposed to water, automatically forms a core/shell structure that can be loaded with insoluble drugs. They are typically between 10–100 nm in size. (C) Liposomes consist of an amphiphilic phospholipid bilayer that encloses hydrophilic substances and are typically between 25 and 2500 nm in size. (D) Niosomes are composed of non-ionic surfactant that form a vesicle to transport aqueous material. They are typically between 25 and 100 nm in size.CC BY · PubMed Central
Figure 5 Drug administration routes to the anterior segment of the eye. (A) Subconjunctival injections are a type of periocular route of administration where the drug is injected under the conjunctiva (epibulbar) or underneath the conjunctiva lining the eyelid (subpalpebral). Intracameral injection delivers medication directly to the anterior chamber/aqueous humor of the eye. Topical administration is most used in drop form and delivers the solution to the exterior of the eye. Intrastromal injection administers the drug directly to the thick, fibrous stroma of the cornea. (B) Figure 3B depicts the layers of the tear film and cornea. The tear film stretches from the lipid layer to the mucous layer and the cornea from the corneal epithelium to the endothelium.
Figure 5 Drug administration routes to the anterior segment of the eye. (A) Subconjunctival injections are a type of periocular route of administration where the drug is injected under the conjunctiva (epibulbar) or underneath the conjunctiva lining the eyelid (subpalpebral). Intracameral injection delivers medication directly to the anterior chamber/aqueous humor of the eye. Topical administration is most used in drop form and delivers the solution to the exterior of the eye. Intrastromal injection administers the drug directly to the thick, fibrous stroma of the cornea. (B) Figure 3B depicts the layers of the tear film and cornea. The tear film stretches from the lipid layer to the mucous layer and the cornea from the corneal epithelium to the endothelium.CC BY · PubMed Central
Figure 6 Drug administration routes to the posterior anatomy of the eye. (A) Intravitreal injections administer the drug directly to the vitreous humor. Suprachoroidal injections deliver directly into the suprachoroidal space. Implants are non-biodegradable systems often anchored to the sclera or injected into the vitreous that release drugs at a predetermined rate. Subretinal injections target the subretinal space or the area directly between retinal pigment epithelium (RPE) cells and photoreceptors. (B) The posterior anatomy of the eye consists of the vitreous humor and the retina, which contains layers of terminally differentiated cells used for light perception.
Figure 6 Drug administration routes to the posterior anatomy of the eye. (A) Intravitreal injections administer the drug directly to the vitreous humor. Suprachoroidal injections deliver directly into the suprachoroidal space. Implants are non-biodegradable systems often anchored to the sclera or injected into the vitreous that release drugs at a predetermined rate. Subretinal injections target the subretinal space or the area directly between retinal pigment epithelium (RPE) cells and photoreceptors. (B) The posterior anatomy of the eye consists of the vitreous humor and the retina, which contains layers of terminally differentiated cells used for light perception.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Research works printed but not linked: 9

  1. Komaromy, 2021, Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP), Investig. Ophthalmol. Vis. Sci., 62, 2783
  2. Visuvanathan, S. (2019). The Effects of AAV-Mediated XIAP Gene Therapy in a Mouse Model of Glaucoma. [Master’s Thesis, Université d’Ottawa/University of Ottawa].
  3. Bilsbury, 2022, AAV-mediated anti-VEGF therapeutics increase corneal allograft survival-rate in a model of high-risk corneal transplantation, Investig. Ophthalmol. Vis. Sci., 63, 72-A0045
  4. Garrigue, 2011, A Comparative Study of Latanoprost-Cationic Emulsion (Catioprost) and Latanoprost Aqueous Solution (Xalatan) in Preclinical Efficacy and Safety Models, Investig. Ophthalmol. Vis. Sci., 52, 238
  5. Biswas, 2017, Niosomes in ocular drug delivery, Eur. J. Pharm. Med. Res, 4, 813
  6. Avti, P., Patel, S., and Sitharaman, B. (2016). Nanobiomaterials Handbook, CRC Press.
  7. Van Ooteghem, M.M. (2019). Biopharmaceutics of Ocular Drug Delivery, CRC Press.
  8. Varma, 2018, Sustained release drug delivery: Closer than you think, Glaucoma Today, 3, 58
  9. Sedlavek, 1965, Possibilities of application of ophthalmic drugs with the aid of gel contact lens, Cesk. Oftalmol., 21, 509

Cited by

See all 52

Metadata

Authors
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H.
Affiliations
University of Massachusetts Chan Medical School (US)
Corresponding author
  • Gao, Guangping
  • Lin, Haijiang
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-09-13
Volume
14
Issue
9
Pages
1931
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4296005586
Cited by
50
References
134
Citations by year
2026: 10 · 2025: 11 · 2024: 14 · 2023: 15
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
BrightFocus Foundation (M2019074)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
ocular drug delivery, ocular gene therapy, adeno-associated virus vectors, vector selection, gene therapy vectors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ocular Drug Delivery: Advancements and Innovations. https://app.cochat.ai/papers/10.3390/pharmaceutics14091931
The paper
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022). Ocular Drug Delivery: Advancements and Innovations. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14091931

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.